CLASS II Device recall · Reported 23 Dec 2020 · FDA Enforcement Report

Tina-quant C-Reactive Protein Gen.3 recalled

Roche Diagnostics Operations is recalling Tina-quant C-Reactive Protein Gen.3, distributed nationwide in the US. The recall was initiated on 6 Nov 2020 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesCRPL3 - lot 42402301
Quantity recalled699 units

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-0634-2021
FDA event ID
86745
Recalling firm
Roche Diagnostics Operations, Indianapolis, IN
Classification
Class II
Status
Terminated
Recall initiated
6 Nov 2020
FDA classified
17 Dec 2020
Reported
23 Dec 2020
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Other Reasons

Timeline

6 Nov 2020Recall initiated by company
17 Dec 2020Classified by FDA+41 days
23 Dec 2020Published in enforcement report+6 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Roche confirmed customer complaints of low quality (QC) recovery and invalid calibrations for the Tina-quant C-Reactive Protein Gen. 3 on the cobas c701 and 702 modules. A discoloration (yellow color) was observed and is the result of cross contamination between the R1 and R3 reagents.

Product as listed by the FDA

Tina-quant C-Reactive Protein Gen.3, Catalog number 05172373190 - Product Usage: the in vitro quantitative determination of CRP in human serum and plasma on Roche automated clinical chemistry analyzers.

Where it was distributed

US Nationwide distribution including in the states of AL, CA, FL, GA, HI, IA, IL, IN, KY, MA, MD, MI, MN, MO, NJ, NY, OH, PA, SC, TN, TX, VA.

Nationwide AlabamaCaliforniaFloridaGeorgiaHawaiiIowaIllinoisIndianaKentuckyMassachusettsMarylandMichiganMinnesotaMissouriNew JerseyNew YorkOhioPennsylvaniaSouth CarolinaTennessee

Questions about this recall

Why was it recalled?

Roche confirmed customer complaints of low quality (QC) recovery and invalid calibrations for the Tina-quant C-Reactive Protein Gen. 3 on the cobas c701 and 702 modules. A discoloration (yellow color) was observed and is the result of cross contamination between the R1 and R3 reagents.

Which lots are affected?

CRPL3 - lot 42402301

Where was it sold?

US Nationwide distribution including in the states of AL, CA, FL, GA, HI, IA, IL, IN, KY, MA, MD, MI, MN, MO, NJ, NY, OH, PA, SC, TN, TX, VA.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Roche Diagnostics Operations

All 127

Other Test Kits & Diagnostics recalls

All 2,663